Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Vadalà M, Poddighe D, Laurino C, Palmieri B.

EPMA J. 2017 Jul 20;8(3):295-311. doi: 10.1007/s13167-017-0101-y. eCollection 2017 Sep. Review.

2.

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Qiu Q, Huang J, Lin Y, Shu X, Fan H, Tu Z, Zhou Y, Xiao C.

Medicine (Baltimore). 2017 Mar;96(11):e6337. doi: 10.1097/MD.0000000000006337. Review.

3.

The Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate Prophylaxis.

Byun JM, Kim HL, Shin DY, Koh Y, Yoon SS, Seong MW, Park SS, Kim JH, Lee YG, Kim I.

PLoS One. 2016 Oct 26;11(10):e0163998. doi: 10.1371/journal.pone.0163998. eCollection 2016.

4.

Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W.

World J Gastroenterol. 2015 Nov 28;21(44):12519-43. doi: 10.3748/wjg.v21.i44.12519. Review.

5.

Pharmacogenetics of treatment response in psoriatic arthritis.

Jani M, Barton A, Ho P.

Curr Rheumatol Rep. 2015 Jul;17(7):44. doi: 10.1007/s11926-015-0518-z. Review.

6.

Adversomics: a new paradigm for vaccine safety and design.

Whitaker JA, Ovsyannikova IG, Poland GA.

Expert Rev Vaccines. 2015 Jul;14(7):935-47. doi: 10.1586/14760584.2015.1038249. Epub 2015 May 2. Review.

7.

Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed.

Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H, Mishima M.

Mol Clin Oncol. 2015 Mar;3(2):334-340. Epub 2014 Nov 4.

8.

Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis.

Peres RS, Liew FY, Talbot J, Carregaro V, Oliveira RD, Almeida SL, França RF, Donate PB, Pinto LG, Ferreira FI, Costa DL, Demarque DP, Gouvea DR, Lopes NP, Queiroz RH, Silva JS, Figueiredo F, Alves-Filho JC, Cunha TM, Ferreira SH, Louzada-Junior P, Cunha FQ.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2509-14. doi: 10.1073/pnas.1424792112. Epub 2015 Feb 9.

9.

Geographical and ethnic distribution of single nucleotide polymorphisms within genes of the folate/homocysteine pathway metabolism.

Binia A, Contreras AV, Canizales-Quinteros S, Alonzo VA, Tejero ME, Silva-Zolezzi I.

Genes Nutr. 2014 Sep;9(5):421. doi: 10.1007/s12263-014-0421-7. Epub 2014 Aug 9.

10.

Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.

Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY.

ScientificWorldJournal. 2014;2014:823763. doi: 10.1155/2014/823763. Epub 2014 May 28.

11.

Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.

Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, Medeiros R.

Biomed Res Int. 2014;2014:368681. doi: 10.1155/2014/368681. Epub 2014 May 21.

12.

Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Davis LA, Polk B, Mann A, Wolff RK, Kerr GS, Reimold AM, Cannon GW, Mikuls TR, Caplan L.

Clin Exp Rheumatol. 2014 May-Jun;32(3):324-32. Epub 2014 Jan 20.

13.

Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.

Li WJ, Jiang H, Fang XJ, Ye HL, Liu MH, Liu YW, Chen Q, Zhang L, Zhang JY, Yuan CL, Zhang QY.

Oncol Lett. 2013 Apr;5(4):1165-1170. Epub 2013 Feb 4.

14.

Pharmacogenetics and pharmacogenomics in rheumatology.

Szekanecz Z, Meskó B, Poliska S, Váncsa A, Szamosi S, Végh E, Simkovics E, Laki J, Kurkó J, Besenyei T, Mikecz K, Glant TT, Nagy L.

Immunol Res. 2013 Jul;56(2-3):325-33. doi: 10.1007/s12026-013-8405-z. Review.

15.

Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.

Davis LA, Cannon GW, Pointer LF, Haverhals LM, Wolff RK, Mikuls TR, Reimold AM, Kerr GS, Richards JS, Johnson DS, Valuck R, Prochazka A, Caplan L.

J Rheumatol. 2013 Jun;40(6):809-17. doi: 10.3899/jrheum.121012. Epub 2013 Apr 1.

16.

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Romão VC, Canhão H, Fonseca JE.

BMC Med. 2013 Jan 23;11:17. doi: 10.1186/1741-7015-11-17. Review.

17.
18.

Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.

Burgos PI, Danila MI, Kelley JM, Hughes LB, Bridges SL Jr.

Ther Adv Musculoskelet Dis. 2009 Apr;1(2):97-105. doi: 10.1177/1759720X09351778.

19.

The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Camilleri M.

Nat Rev Gastroenterol Hepatol. 2012 Feb 7;9(3):173-84. doi: 10.1038/nrgastro.2012.2. Review.

20.

The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity.

Taşbaş O, Borman P, Gürhan Karabulut H, Tükün A, Yorgancıoğlu R.

Open Rheumatol J. 2011;5:30-5. doi: 10.2174/1874312901105010030. Epub 2011 Oct 14.

Supplemental Content

Support Center